IL1B and neoplasm: Notably, inhibition of HDAC6 with Tubastatin A markedly slowed tumour growth, lowered IL-1β levels, and shifted the immune landscape toward an anti-tumour profile; reducing M2 macrophages while enhancing M1 macrophage responses.